EUCTR2015-000181-60-NL进行中（未招募）1 期
A Multi-Center, Randomized, Double-Blind, Three-Arm, Parallel-Group trial to assess the efficacy and safety of NTRA-9620 in infants with Short Bowel Syndrome (SBS) following surgical resection. - GIFT-02
utrinia Ltd.0 个研究点目标入组 150 人开始时间: 2017年2月14日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 150
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Subjects must meet all of the following criteria to be included:
- •1)Subject must be at least 28 weeks post-menstrual age and up to 52 weeks chronological age at enrollment.
- •2)Subject weight must be at least 500 grams (17.6 ounces) at time of enrollment.
- •3)Clinically diagnosed with SBS requiring PN/IV secondary to surgical resection of the intestine.
- •4)After major surgical resection leading to SBS, the subject has maximally 70% of expected bowel length preserved or an ostomy in place such that = 70% of the small bowel is available for absorption .
- •5)Subject can tolerate at least 10 mL/kg/day of enteral nutrition (EN) for at least 7 days at time of enrollment.
- •6)At time of enrollment subject is on at least 70% of prescribed PN/IV and no more than 30% of EN based on total caloric intake for at least 7 days prior to study entry.
- •7)Subject is randomized into the trial within 4 months from the surgical resection that has led to the diagnosis of SBS.
- •8)Subject’s parent(s) or legal guardian(s) provide written informed consent.
- •9)Subject’s parent(s) or legal guardian(s) understand and are willing to comply with all study procedures and requirements.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 150
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range 0
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range 0
排除标准
- •Subjects meeting any of the following criteria at study entry will be excluded:
- •1)Subject has undergone any bowel lengthening procedure.
- •2)Subject has a malabsorption disorder such as:
- •Congenital etiology (such as microvilli inclusion disease, tufting enteropathy)
- •Untreated Hirchsprung’s disease
- •3)Significant motility disorder such as:
- •Pseudo obstruction
- •Severe gastroschisis defined as: primary reason for PN support is due to persistent feeding intolerance of less than 20 ml/kg/day EN intake or signs and symptoms (i.e., abdominal distention, vomiting) requiring prokinetic agents.
- •4)Any known inherited abnormality (e.g., Fanconi syndrome,) that is not related to SBS.
- •5)Prior bowel resection due to isolated spontaneous intestinal perforation.
- •6)< 10 cm of remaining small bowel left with no colon.
- •7)Uncontrolled systemic infection, acute gastroenteritis, pneumonia, cardiovascular or other abnormality including EKG findings that in the opinion of the investigator makes the infant unstable and at significant risk of not completing the first 12 weeks of the study.
- •8)Subjects with known hyperinsulinemia .
- •9)Subjects with unexplained or recurrent hypoglycemia with blood glucose = 50 mg/dL within 48 hours of treatment initiation.
- •10)Subjects with severe anemia of Hemoglobin less than 60 g/L and requiring transfusion within 48 hours of treatment initiation to avoid a life threatening event.
- •11)Subjects who require pancreatic enzyme replacement therapy.
- •12)Subject is currently receiving oral or injectable insulin for any reason.
- •13)Participation in another interventional clinical study within the past 30 days that may interfere with the results of this study.
- •14)History or current use of growth factors or glutamine.
- •15)In the opinion of the investigator, the subject has any other medical condition that would make participation in this study either unsafe or would compromise the potential benefit of insulin treatment
研究者
相似试验
撤回
2 期
A Multi-Center, Randomized, Double-Blind, Three-Arm, Parallel-Group Trial to Assess the Efficacy and Safety of NTRA-9620 in Infants with Short Bowel Syndrome (SBS) Following Surgical ResectioSBSNL-OMON45489utrinia Ltd15
已完成
不适用
A study to evaluate the comparison of Tretinon cream to Retin A in the acne vulgarisCTRI/2021/11/038190Aleor Dermaceuticals Limited India500
招募中
不适用
A study to evaluate the comparison of Tretinoin cream to Retin A and placebo in the acne vulgarisCTRI/2022/11/047525Aleor Dermaceuticals Limited India (Alembic Pharmaceuticals Limited)
已完成
不适用
Clinical Bioequivalence Study of Nitazoxanide Tablets for patients with Diarrhea caused by Giardia Lamblia.CTRI/2022/06/043433Annora Pharma Private Limited390
已完成
不适用
A Clinical Study to Evaluate the Efficacy and Safety of Ketoconazole Shampoo in Subjects with Tinea Versicolor.CTRI/2022/03/041524Cadila Healthcare Limited425